Top Markets
#1 Akedo Akedo +63.33%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.58%
#4 Cross Cross +34.01%
#5 Black Phoenix Black Phoenix +33.94%
#6 Cap Cap +32.66%
#7 Velvet Velvet +25.73%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.06%
#9 Ravencoin Ravencoin +13.84%
#10 DoubleZero DoubleZero +13.55%
Coin of the day
Akedo Akedo
設定
言語
日本
通貨
USD
テーマ
Valion Bio, Inc. Valion Bio, Inc.

Valion Bio, Inc.

VBIO
株式のランク #38911
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
株価
$0.1645
時価総額
$681.26K
変化（1日）
-3.69%
変化（1年）
-95.30%
国
US
取引 Valion Bio, Inc. (VBIO)

カテゴリー

Healthcare
Valion Bio, Inc.（VBIO）のP/B比率
2026 時点のP/B比率 TTM: 0
Valion Bio, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0 です。2026 年末時点でのP/B比率は 0 でした。
Valion Bio, Inc. の P/B 比率の履歴（2026 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE